{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["14"],"submitter":["Meng X"],"pubmed_abstract":["<h4>Background</h4>Conditional survival (CS) is defined as the possibility of further survival after patients have survived for several years since diagnosis. This may be highly valuable for real-time prognostic monitoring, especially when considering individualized factors. Such prediction tools were lacking for non-metastatic triple-negative breast cancer (TNBC). Therefore, this study estimated CS and developed a novel CS-nomogram for real-time prediction of 10-year survival.<h4>Methods</h4>We recruited 32,836 non-metastatic TNBC patients from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2019), who were divided into training and validation groups according to a 7:3 ratio. The Kaplan-Meier method estimated overall survival (OS), and the CS was calculated using the"],"journal":["Frontiers in endocrinology"],"pagination":["1119105"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9998975"],"repository":["biostudies-literature"],"pubmed_title":["A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer."],"pmcid":["PMC9998975"],"pubmed_authors":["Guo Y","Cai Y","Meng X","Chang X"],"additional_accession":[]},"is_claimable":false,"name":"A novel conditional survival nomogram for monitoring real-time prognosis of non-metastatic triple-negative breast cancer.","description":"<h4>Background</h4>Conditional survival (CS) is defined as the possibility of further survival after patients have survived for several years since diagnosis. This may be highly valuable for real-time prognostic monitoring, especially when considering individualized factors. Such prediction tools were lacking for non-metastatic triple-negative breast cancer (TNBC). Therefore, this study estimated CS and developed a novel CS-nomogram for real-time prediction of 10-year survival.<h4>Methods</h4>We recruited 32,836 non-metastatic TNBC patients from the Surveillance, Epidemiology, and End Results (SEER) database (2010-2019), who were divided into training and validation groups according to a 7:3 ratio. The Kaplan-Meier method estimated overall survival (OS), and the CS was calculated using the","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023","modification":"2025-04-04T18:49:11.732Z","creation":"2025-04-04T18:49:11.732Z"},"accession":"S-EPMC9998975","cross_references":{"pubmed":["36909305"],"doi":["10.3389/fendo.2023.1119105"]}}